文献速递胸部技术与安全PETCTMR

PET/CT在一线酪氨酸激酶抑制剂治疗的晚期EGFR突变非小细胞肺癌患者中识别寡转移/寡进展性疾病的临床价值:来自生存比较的启示

Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
PubMed 文献 · Br J Radiol · 2022-06-09

该回顾性研究纳入392例接受一线EGFR-TKI治疗的转移性EGFR突变NSCLC患者,比较基线PET/CT与常规影像(CIM)识别寡转移(OMD)和寡进展(OPD)的能力及生存差异。PET/CT组OMD检出率22.7%(53/233)vs CIM组18.2%(29/159),差异无统计学意义(p=0.171);PET/CT组中OMD患者PFS更长(p=0.016),OPD检出率63.0%(34/54)vs CIM组35.0%(39/110)(p=0.003),PET/CT组中OPD患者OS2显著更长(p=0.011)。结论提示PET/CT评估的OMD/OPD患者生存结局更优。

要点

  • PET/CT组OMD检出率22.7%(53/233) vs CIM组18.2%(29/159),差异无统计学意义(p=0.171)。
  • PET/CT组中OMD患者PFS较MMD患者更长(p=0.016),OS有改善趋势(p=0.058)。
  • PET/CT组OPD检出率63.0%(34/54) vs CIM组35.0%(39/110),差异有统计学意义(p=0.003)。

核心结论

  • 在一线EGFR-TKI治疗的转移性NSCLC患者中,经PET/CT(而非CIM)评估的OMD/OPD患者,其生存结局通常优于MMD/MPD患者。

研究设计与样本

  • 回顾性筛选连续病例,纳入接受基线PET/CT和脑MRI或完整常规影像(CIM,包括脑MRI、胸部CT、腹部超声或CT及骨显像)的转移性EGFR突变NSCLC患者,共评估392例。

诊断标准与关键数值

  • OMD/OPD定义为最多5个病灶和3个器官的转移/进展;否则定义为多转移/多进展性疾病(MMD/MPD)。PET/CT组OMD检出率22.7%(53/233) vs CIM组18.2%(29/159),p=0.171;PET/CT组OPD检出率63.0%(34/54) vs CIM组35.0%(39/110),p=0.003。

临床应用与阅片要点

  • 原文结论提示,PET/CT似乎影响一线EGFR-TKI治疗的转移性NSCLC伴OMD/OPD患者的生存。

局限性

  • 回顾性筛选病例。
  • 仅164例(55.2%)患者有足够影像学扫描以全面分析首次疾病进展(FPD)时的肿瘤分布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Local therapy (LT) could potentially prolong the survival of patient with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs) and harboring oligometastatic/oligoprogressive disease (OMD/OPD). However, the optimal imaging method for identifying patients with OMD/OPD remains controversial. The objective of this study was to investigate the clinical value of incorporating PET/CT in detecting patients with OMD/OPD.

METHODS: Consecutive cases with metastatic EGFR-mutant NSCLC undergoing first-line EGFR-TKI treatment were retrospectively screened and those receiving baseline PET/CT and brain magnetic resonance imaging (MRI) or complete conventional imaging (CIM), including brain MRI, chest computed tomography (CT), abdomen ultrasound or CT and bone scintigraphy were included. OMD/OPD was defined as metastases/progressions documented at a maximum of five lesions and three organs, otherwise was defined as multiple metastatic/progressive disease (MMD/MPD). Progression-free survival (PFS) and overall survival (OS) were analyzed.

RESULTS: Of the 392 patients evaluated, baseline OMD was detected in 22.7% (53/233) of patients by PET/CT and in 18.2% (29/159) of patients by CIM (p = 0.171). Among the patients evaluated with baseline PET/CT, patients with OMD had longer PFS (p = 0.016) and tendency of improved OS (p = 0.058) than those with MMD. However, this result was not observed with patients evaluated using baseline CIM. With a median follow-up of 24.2 (range, 1.1-124.6) months, 297 patients had their first disease progression (FPD), of whom 164 (55.2%) had adequate imaging scans to analyze the tumor distributions at FPD comprehensively. OPD was detected in 63.0% (34/54) and 35.0% (39/110) of patients among the PET/CT and CIM assessed group (p = 0.003), respectively. Among the PET/CT assessed group, patients with OPD had significantly longer post-progressive overall survival (OS2) than those with MPD (p = 0.011). However, no significant difference of OS2 in the CIM assessed group was found.

CONCLUSION: Patients with OMD/OPD, evaluated by PET/CT but not CIM, generally had more favorable survival outcomes than those with MMD/MPD among patients with metastatic NSCLC undergoing first-line EGFR-TKI treatment.

ADVANCES IN KNOWLEDGE: PET/CT seems to affect the survival of patients under first-line EGFR-TKI treated metastatic NSCLC with OMD/OPD.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Xu, Yu, Guo, et al. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. Br J Radiol. 2022. PMID: 35611637. doi:10.1259/bjr.20220035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。